Published in J Hosp Med on September 01, 2010
RIGOR guidelines: escalating STAIR and STEPS for effective translational research. Transl Stroke Res (2012) 1.45
Early stroke mortality, patient preferences, and the withdrawal of care bias. Neurology (2012) 1.07
Signaling via the prostaglandin E₂ receptor EP4 exerts neuronal and vascular protection in a mouse model of cerebral ischemia. J Clin Invest (2011) 1.06
Trends in stroke rates, risk, and outcomes in the United States, 1988 to 2008. Am J Med (2014) 1.03
Isoflurane postconditioning induces neuroprotection via Akt activation and attenuation of increased mitochondrial membrane permeability. Neuroscience (2011) 1.02
The role of astrocytes in mediating exogenous cell-based restorative therapy for stroke. Glia (2013) 1.00
Astrocytes, therapeutic targets for neuroprotection and neurorestoration in ischemic stroke. Prog Neurobiol (2015) 0.99
Critical early thrombolytic and endovascular reperfusion therapy for acute ischemic stroke victims: a call for adjunct neuroprotection. Transl Stroke Res (2015) 0.87
Thrombolysis ImPlementation in Stroke (TIPS): evaluating the effectiveness of a strategy to increase the adoption of best evidence practice--protocol for a cluster randomised controlled trial in acute stroke care. Implement Sci (2014) 0.86
Emerging Therapies: Pleiotropic Multi-target Drugs to Treat Stroke Victims. Transl Stroke Res (2011) 0.85
Regulatory CD8(+)CD122 (+) T-cells predominate in CNS after treatment of experimental stroke in male mice with IL-10-secreting B-cells. Metab Brain Dis (2014) 0.84
Motor System Reorganization After Stroke: Stimulating and Training Toward Perfection. Physiology (Bethesda) (2015) 0.83
How can we improve stroke thrombolysis rates? A review of health system factors and approaches associated with thrombolysis administration rates in acute stroke care. Implement Sci (2016) 0.82
Fast neuroprotection (fast-NPRX) for acute ischemic stroke victims: the time for treatment is now. Transl Stroke Res (2013) 0.82
Drug-like property profiling of novel neuroprotective compounds to treat acute ischemic stroke: guidelines to develop pleiotropic molecules. Transl Stroke Res (2013) 0.81
The neuroprotective properties of the superoxide dismutase mimetic tempol correlate with its ability to reduce pathological glutamate release in a rodent model of stroke. Free Radic Biol Med (2014) 0.79
Outcomes after acute ischemic stroke in the United States: does residential ZIP code matter? J Am Heart Assoc (2015) 0.78
Why don't more patients receive intravenous rt-PA for acute stroke? Expert Rev Neurother (2015) 0.76
Maximizing efficiency and diagnostic accuracy triage of acute stroke patients: A case-control study. Interv Neuroradiol (2016) 0.75
Agreement with evidence for tissue Plasminogen Activator use among emergency physicians: a cross-sectional survey. BMC Res Notes (2015) 0.75
Effect of the Pleiotropic Drug CNB-001 on Tissue Plasminogen Activator (tPA) Protease Activity in vitro: Support for Combination Therapy to Treat Acute Ischemic Stroke. J Neurol Neurophysiol (2014) 0.75
Imaging of prehospital stroke therapeutics. Expert Rev Cardiovasc Ther (2015) 0.75
Tissue plasminogen activator; identifying major barriers related to intravenous injection in ischemic acute cerebral infraction. J Res Med Sci (2017) 0.75
Increase in national intravenous thrombolysis rates for ischaemic stroke between 2005 and 2012: is bigger better? BMC Neurol (2016) 0.75
Mesenchymal Stromal Cells Promote Axonal Outgrowth Alone and Synergistically with Astrocytes via tPA. PLoS One (2016) 0.75
Use of intravenous tissue plasminogen activator and hospital costs for patients with acute ischaemic stroke aged 18-64 years in the USA. Stroke Vasc Neurol (2016) 0.75
Rate of intravenous thrombolysis for acute ischaemic stroke in the North-of-France region and evolution over time. J Neurol (2014) 0.75
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol (1992) 60.45
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med (1995) 47.15
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet (2004) 12.92
Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet (2007) 10.74
Recommendations for the establishment of primary stroke centers. Brain Attack Coalition. JAMA (2000) 7.25
Stroke severity in atrial fibrillation. The Framingham Study. Stroke (1996) 4.11
Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA (2000) 3.43
National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke (2008) 3.40
Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity. Stroke (2001) 3.17
Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke (2004) 2.97
Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med (1999) 2.82
Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. Neurology (2005) 2.81
Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol (2004) 2.65
Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol (2001) 1.66
Thrombolysis for ischemic stroke in the United States: data from National Hospital Discharge Survey 1999-2001. Neurosurgery (2005) 1.60
Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke (2003) 1.58
TPA use for stroke in the Registry of the Canadian Stroke Network. Can J Neurol Sci (2005) 1.58
Management of acute ischaemic stroke: new guidelines from the American Stroke Association and European Stroke Initiative. Lancet Neurol (2003) 1.40
Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke (1998) 1.34
Why are stroke patients excluded from tPA therapy? An analysis of patient eligibility. Neurology (2001) 0.88
Intravenous t-PA for acute ischemic stroke: therapeutic yield of a stroke code system. Neurology (1998) 0.87
Views of practicing physicians and the public on medical errors. N Engl J Med (2002) 7.15
Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood) (2008) 6.13
Incidence and mortality of hip fractures in the United States. JAMA (2009) 6.05
Forecasting the effects of obesity and smoking on U.S. life expectancy. N Engl J Med (2009) 5.64
The value of medical spending in the United States, 1960-2000. N Engl J Med (2006) 5.38
The gap gets bigger: changes in mortality and life expectancy, by education, 1981-2000. Health Aff (Millwood) (2008) 4.94
Medicare and cost-effectiveness analysis. N Engl J Med (2005) 4.20
Trends in the prevalence and mortality of cognitive impairment in the United States: is there evidence of a compression of cognitive morbidity? Alzheimers Dement (2008) 4.00
Value-based insurance design. Health Aff (Millwood) (2007) 3.27
Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med (2005) 2.60
Bias in published cost effectiveness studies: systematic review. BMJ (2006) 2.60
Increased spending on health care: how much can the United States afford? Health Aff (Millwood) (2003) 2.41
Prescription drug spending trends in the United States: looking beyond the turning point. Health Aff (Millwood) (2008) 2.37
Mortality reduction among pneumonia patients still substantial despite the impact of coding changes. Am J Med (2013) 2.14
Hospitalizations and deaths among adults with cardiovascular disease who underuse medications because of cost: a longitudinal analysis. Med Care (2010) 2.05
Explaining racial differences in prostate cancer mortality. Cancer (2012) 1.82
Delays in publication of cost utility analyses conducted alongside clinical trials: registry analysis. BMJ (2004) 1.77
Linking cost sharing to value: an unrivaled yet unrealized public health opportunity. Ann Intern Med (2007) 1.65
Increasing health insurance costs and the decline in insurance coverage. Health Serv Res (2005) 1.61
Impact of insurance and supply of health professionals on coverage of treatment for hypertension in Mexico: population based study. BMJ (2007) 1.60
Effects of increased patient cost sharing on socioeconomic disparities in health care. J Gen Intern Med (2008) 1.56
Challenges in building disease-based national health accounts. Med Care (2009) 1.50
Pain management in nursing home residents with cancer. J Am Geriatr Soc (2015) 1.49
Trends in the measurement of health utilities in published cost-utility analyses. Value Health (2006) 1.47
Growth and quality of the cost-utility literature, 1976-2001. Value Health (2005) 1.42
Trends in medical spending by age, 1963-2000. Health Aff (Millwood) (2004) 1.42
Comparison of trends in US health-related quality of life over the 2000s using the SF-6D, HALex, EQ-5D, and EQ-5D visual analog scale versus a broader set of symptoms and impairments. Med Care (2014) 1.41
Cost-effectiveness of coronary MDCT in the triage of patients with acute chest pain. AJR Am J Roentgenol (2008) 1.37
Marked reduction in 30-day mortality among elderly patients with community-acquired pneumonia. Am J Med (2011) 1.36
Clinical outcomes and cost-effectiveness of coronary computed tomography angiography in the evaluation of patients with chest pain. J Am Coll Cardiol (2009) 1.34
Disability and the future of Medicare. N Engl J Med (2003) 1.32
Increased spending on health care: long-term implications for the nation. Health Aff (Millwood) (2009) 1.23
Cost-utility analyses in orthopaedic surgery. J Bone Joint Surg Am (2005) 1.22
Trends in cost effectiveness analyses in orthopaedic surgery. Clin Orthop Relat Res (2007) 1.22
Cost-utility analysis studies of depression management: a systematic review. Am J Psychiatry (2004) 1.21
The ACO rules--striking the balance between participation and transformative potential. N Engl J Med (2011) 1.18
Evidence that value-based insurance can be effective. Health Aff (Millwood) (2010) 1.17
The impact of symptoms and impairments on overall health in US national health data. Med Care (2008) 1.11
A bibliometric review of cost-effectiveness analyses in the economic and medical literature: 1976-2006. Med Decis Making (2010) 1.08
The value of medical interventions for lung cancer in the elderly: results from SEER-CMHSF. Cancer (2007) 1.04
Psychological distress and trends in healthcare expenditures and outpatient healthcare. Am J Manag Care (2011) 1.03
Girls' education and HIV risk: evidence from Uganda. J Health Econ (2013) 1.01
Can we better prioritize resources for cost-utility research? Med Decis Making (2005) 0.99
Adoption and spread of new imaging technology: a case study. Health Aff (Millwood) (2009) 0.93
US trends in quality-adjusted life expectancy from 1987 to 2008: combining national surveys to more broadly track the health of the nation. Am J Public Health (2013) 0.91
Overuse of antidepressants in a nationally representative adult patient population in 2005. Psychiatr Serv (2011) 0.88
Disability forecasts and future Medicare costs. Front Health Policy Res (2004) 0.88
The value of coronary heart disease care for the elderly: 1987-2002. Health Aff (Millwood) (2007) 0.88
Rising out-of-pocket costs in disease management programs. Am J Manag Care (2006) 0.87
Medical spending differences in the United States and Canada: the role of prices, procedures, and administrative expenses. Inquiry (2010) 0.84
Trends in mortality and medical spending in patients hospitalized for community-acquired pneumonia: 1993-2005. Med Care (2010) 0.84
A synthesis of cost-utility analysis literature in infectious disease. Lancet Infect Dis (2005) 0.84
Diffusion of published cost-utility analyses in the field of health policy and practice. Int J Technol Assess Health Care (2005) 0.83
Ultraviolet index and racial differences in prostate cancer incidence and mortality. Cancer (2013) 0.82
Grounding coverage in value: a paradigm for linking quality and costs. Med Care (2006) 0.82
A controlled trial of value-based insurance design - the MHealthy: Focus on Diabetes (FOD) trial. Implement Sci (2009) 0.81
Policy makers will need a way to update bundled payments that reflects highly skewed spending growth of various care episodes. Health Aff (Millwood) (2013) 0.80
Do drug formulary policies reflect evidence of value? Am J Manag Care (2006) 0.79
Potential consequences of reforming Medicare into a competitive bidding system. JAMA (2012) 0.78
The 'graying' of group health insurance. Health Aff (Millwood) (2006) 0.78
Health care in the next administration. N Engl J Med (2008) 0.78
Why health reform will bend the cost curve. Issue Brief (Commonw Fund) (2009) 0.78
Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation. Am J Cardiol (2004) 0.78
Short-term Outcomes for Medicare Beneficiaries After Low-acuity Visits to Emergency Departments and Clinics. Med Care (2016) 0.75
Recent national trends in acute myocardial infarction hospitalizations in Medicare: shrinking declines and growing disparities. Epidemiology (2015) 0.75
Confronting hysteria: a reply to Fairman and Curtiss. J Manag Care Pharm (2008) 0.75
The reply. Am J Med (2013) 0.75
Cost savings associated with expanded hospice use in Medicare. J Palliat Med (2015) 0.75
Enhancing Administrative Data to Predict Emergency Department Utilization: The Role of Neighborhood Sociodemographics. J Health Care Poor Underserved (2017) 0.75
Efficiencies, jobs, and staying the course. Interview by John Marcille. Manag Care (2013) 0.75
Health insurance and the American public sector labor market. J Health Econ (2014) 0.75
Potential impact of Affordable Care Act-related insurance expansion on trauma care reimbursement. J Trauma Acute Care Surg (2017) 0.75